Sandoz resubmits biosimilar pegfilgrastim application to US FDA

NEXT STORY
Oncology Venture har bekräftat registreringsstrategin för dovitinib och utvecklat ny DRP-kombinationsbiomarkör för PD1 / PD-L1 + dovitinib – inleder utlicensieringsaktiviteter med Destum Partners
PREV STORY
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller

WALTHAM, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website

TEL-AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...

author_avatar
NASDAQ Market News

Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency

COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

author_avatar
NASDAQ Market News